Thursday, May 26, 2016 2:41:51 PM
This has been said repeatedly on this board. Apparently investors don't understand what they invest in!?
Well...I don't think investors see the Company's product as anything else than an enhancement to a product that exist already, ie silk! So, from that stand point, investors don't understand why the Company keeps presenting new strains of the same product but cannot mass produce it???
Hard to understand that new strains of material keep poping out while the Company has difficulties getting the desired quality and consistency on the first strain in order to mass produce it?!
This sends the message to investors that the Company is good at R&D but unable to produce (most companies that do that cease to exist eventually).
While investors should understand what they invest in, they cannot be blamed for being ignorant on everything the Company has to do to produce the product it developed. The Company is responsible to explain to the investors the steps that are required to produce the product it developed (it should have the knowledge of the hurdles and be able to communicate this to the investors to set the right expectations). This is something that was very poorly done by the Company and further damage was done by putting unrealistic timelines for comnercial production! It set false expectations, so the investor's understanding is not really what needs to be blamed...
Jonnyo07
Good things come to those who can wait...
Recent KBLB News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:31:54 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 09:30:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:43:51 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/11/2023 08:30:50 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:15 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:30:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:35:05 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM